Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Guidelines versus clinical practice--which therapy and which device?

J Christian Virchow1

  • 1Department of Pneumology, University Medical Clinic, 18057 Rostock, Germany. j.c.virchow@med.uni-rostock.de

Respiratory Medicine
|October 16, 2004
PubMed
Summary

Improvements in dry powder inhaler (DPI) technology, like the Novolizer, can enhance inhaled asthma therapy more than new drugs. These devices offer better safety and efficacy for patients with asthma and COPD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remission in Global Airway Diseases: EUFOREA Consensus Paper.

Allergy·2026
Same author

Reply to Zhao et al.: Clarifying Structural - Functional Coupling by FeNO Status in VESTIGE.

American journal of respiratory and critical care medicine·2026
Same author

Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: A post hoc analysis.

The journal of allergy and clinical immunology. In practice·2026
Same author

The Role of Biologics in Reducing Mucous Plug Burden in Asthma.

Allergy·2025
Same author

Moving towards asthma remission from mechanistic understanding to clinical practice.

Current opinion in allergy and clinical immunology·2025
Same author

Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial.

American journal of respiratory and critical care medicine·2025

Area of Science:

  • Pulmonary Medicine
  • Medical Device Technology

Background:

  • Inhalation therapy is the primary treatment for asthma, delivering medication directly to the lungs.
  • Current asthma management often involves inhaled corticosteroids and short-acting beta2-agonists.
  • Future advancements in asthma treatment are expected to come from improved inhaler technology.

Purpose of the Study:

  • To evaluate the advancements in dry powder inhaler (DPI) technology for inhaled therapy.
  • To highlight the features of the Novolizer DPI that enhance safety and efficacy.
  • To discuss the potential of refined DPIs in improving asthma and COPD management.

Main Methods:

  • Review of dry powder inhaler (DPI) technology advancements.
  • Focus on the Novolizer DPI and its specific features.

Related Experiment Videos

  • Comparison of DPIs with traditional metered dose inhalers.

    • Main Results:

    • Dry powder inhalers (DPIs) offer advantages over metered dose inhalers, including simplified usage.
    • The Novolizer DPI features an inspiratory trigger threshold to prevent underdosing.
    • An overdose prevention mechanism is included in the Novolizer to prevent repeated activation without inhalation.

    Conclusions:

    • Technically refined DPIs hold greater potential for advancing inhaled anti-asthmatic therapy than new inhaled drugs.
    • Improved inhaler technology is crucial for optimizing treatment for asthma and chronic obstructive pulmonary disease (COPD).
    • The Novolizer represents a significant development in DPI technology, enhancing patient safety and therapeutic efficacy.